ivermectin for scabies – Why ivermectin is a better choice than permethrin

Description of the potential effects of the substance Ivermectin based on the literature. (This is not a product description, disclaimer at the bottom of the page)

Scabies is a contagious parasitic skin infection caused by mites Sarcoptes scabiei var. hominis. Despite being microscopic organisms, their impact on human health is far from negligible. The mites burrow into the superficial layer of the skin, lay eggs and trigger an intense immune response that causes constant itching, redness and characteristic thread-like tunnels. (¹⁾Due to its highly infectious nature, scabies remains a common public health challenge worldwide, affecting both developed and developing regions, with an estimated 200-300 million cases per year. The disease does not discriminate against anyone; it occurs in people of all ages, ethnic groups and socio-economic backgrounds, although the incidence is higher in crowded environments where close personal contact is common. (²⁾

The characteristic symptom of scabies is severe itching, especially at night, which disrupts sleep and significantly reduces quality of life. The itching is often accompanied by a rash that may resemble eczema or allergic reactions, making clinical diagnosis difficult without a thorough history and examination. Typical sites of occurrence include the spaces between the fingers, wrists, elbows, armpits, waist and genital area. Unusual symptoms, such as scalp or nail involvement, may occur in infants and elderly patients. Although scabies in itself is not fatal, its complications can be serious. Persistent scratching can cause damage to the skin, which opens the way to bacterial superinfections, most commonly caused by Streptococcus pyogenes or Staphylococcus aureus. In resource-limited environments, these infections can develop into cellulitis, septicaemia and even indirectly contribute to the development of chronic diseases such as rheumatic heart disease. (³⁾  (⁴⁾

Transmission of scabies is mainly through prolonged skin-to-skin contact, making households, nursing homes, prisons and refugee camps the places where outbreaks are most common. Shared clothing, towels and bedding also contribute to the spread of the disease, although to a lesser extent than direct contact. The problem is often exacerbated by the social stigma associated with scabies, which makes those affected hesitate to seek treatment until symptoms become unbearable. Untreated infestation can persist indefinitely and spread unnoticed in communities. (⁵⁾

The public health importance of scabies has only recently been recognised internationally. In 2017. The World Health Organisation (WHO) added scabies to the list of neglected tropical diseases, highlighting its burden on health systems and the urgent need for more effective management strategies . The inclusion of the disease in the list reflects the growing awareness that scabies is not just a nuisance, but a driver of significant morbidity, particularly in tropical and resource-poor regions. ⁽⁶⁾

Current first-line treatment is based on topical permethrin and oral ivermectin, which act directly on the mites. However, increasing reports of permethrin treatment failures have caused concern among clinicians and researchers. This emerging challenge highlights the importance of revisiting scabies treatment options and seeking alternative therapies that provide better outcomes, especially for patients with recurrent or resistant infections. Understanding scabies in all its dimensions - biology, clinical features, transmission dynamics and complications - provides a basis for understanding why some treatments may fail and others, such as ivermectin, are gaining recognition as more reliable solutions. Scabies is not just a skin condition; it is a public health problem whose persistence and complications require renewed attention and innovative therapeutic approaches. (⁶⁾

Standard treatment: permethrin

For several decades, permethrin cream (5%) has been the primary drug used to treat scabies worldwide. Classified as a synthetic pyrethroid, permethrin works by interfering with sodium transport channels in the nervous system of scabies mites, causing paralysis and ultimately death. Due to its targeted action, relatively low toxicity and ease of topical application, it has quickly become the gold standard for both individual treatment and control of outbreaks in community and institutional settings. (⁷⁾

The standard treatment consists of applying permethrin cream to the entire body from the neck down, leaving it on for 8-14 hours and then washing it off. In babies and young children, the scalp and face (excluding the eyes and mouth) are also treated, as these areas are often affected. A repeat application after one week is usually recommended to ensure elimination of newly hatched mites, as permethrin has limited insecticidal activity. When used correctly in combination with home treatment and decontamination of clothing and bedding, permethrin has historically achieved cure rates in excess of 90%. (⁷⁾

Nevertheless, there is growing evidence that permethrin resistance may become a reality. Clinical reports from various parts of the world describe cases of patients who did not develop an adequate response despite proper use, adequate dosage and simultaneous treatment of those in contact with the patient. Laboratory studies point to possible mutations in mite sodium channel genes that may reduce permethrin's binding affinity and thus impair its efficacy. In addition, metabolic resistance, in which mites increase detoxification enzymes to break down the drug, has been proposed as another mechanism. Although large-scale molecular studies are still limited, these concerns have led researchers and clinicians to question the long-term efficacy of permethrin as the only first-line therapy. (⁸⁾

Logistical and practical barriers are another limitation of permethrin. The need to apply the product to the whole body, particularly in elderly or disabled patients, is often inconvenient. Although relatively rare, skin irritation may occur, further discouraging the use of the drug. In endemic regions, the cost and availability of permethrin cream can also be a barrier, limiting its usefulness in large-scale public health programmes. As scabies continues to be recognised as a serious global health problem, reliance on permethrin alone is becoming increasingly problematic. Increasing reports of treatment failures, due to resistance, reinfection or difficulties in application, highlight the urgent need to seek alternative or complementary therapeutic strategies. The growing discrepancy between clinical needs and therapeutic efficacy has led to oral ivermectin being considered not only as a second-line option, but in many cases as a more practical and effective first-line solution. (⁸⁾

Why permethrin sometimes fails

Although permethrin has been a mainstay of scabies treatment for decades, its efficacy in real-world settings has become increasingly patchy. Patients and clinicians alike report situations where symptoms persist or recur despite apparently correct use. To understand why permethrin sometimes fails, it is necessary to examine the combination of biological, clinical and logistical factors that combine to undermine its efficacy.

Incomplete or incorrect application

One of the most common reasons for treatment failure is incomplete or incorrect application. For permethrin to work, it must be applied thoroughly over the entire body surface, covering even less obvious areas such as soles of the feet, spaces under the nails and skin folds. In practice, patients may miss some areas, apply too thin a layer or wash off the cream before the recommended contact time of 8-14 hours. Without complete coverage, some mites survive, multiply and maintain the infection. This problem is exacerbated in households where only the symptomatic person is treated; untreated people in close contact with the sick person can easily re-infect others, giving the impression that the medication is not working. (⁹⁾

Patient compliance

Another important factor is patient compliance. The application of permethrin is labour-intensive, especially in the case of children, the elderly or people with limited mobility who are unable to apply the product to the whole body themselves. Often neglected is the re-application of the preparation after one week, which is necessary to control mites hatched from surviving eggs. Even in clinical trials where instructions are carefully explained, adherence rates are not ideal, and in real-world settings it is even more difficult to ensure adherence. ⁽⁹⁾

Biological resistance

In addition to compliance issues, emerging biological resistance in Sarcoptes scabiei. Like bacteria that develop resistance to antibiotics, scabies mites appear to be able to adapt to chemical agents. Mutations in sodium channel proteins - the main target of permethrin - may reduce the binding capacity of the drug, reducing its efficacy. In addition, mites may develop metabolic adaptations by increasing the activity of detoxification enzymes that break down permethrin before it can take effect. Although large-scale genetic surveillance studies are still limited, clusters of resistance cases have been reported in several regions, suggesting that this is not a theoretical issue but an evolving clinical reality. (⁹⁾

No insecticidal effect

The lack of insecticidal action is another limitation of permethrin. Although it effectively kills adult mites and larvae, the eggs often remain intact. If the treatment is not repeated after a week to control newly hatched mites, the infestation may return. Patients who do not understand this requirement may assume that one application is enough and then experience a relapse. This cycle of partial treatment and reinfection can easily be misinterpreted as drug resistance. ⁽⁹⁾

Socio-economic barriers

Finally, socio-economic barriers play a role. In resource-limited settings, access to permethrin may be limited, leading to diluted or incomplete treatment cycles. Families may share one tube among several members, reducing the effective dose for each person. In addition, the stigma associated with scabies sometimes stops patients from seeking prompt treatment, making infections more severe and difficult to treat.

In summary, these factors show that permethrin failure is rarely due to a single cause. Rather, it reflects a complex interaction between human behaviour, biological adaptations of mites and structural challenges in healthcare delivery. Recognition of these limitations is essential to rethink scabies treatment and highlights the need for alternative approaches, such as oral ivermectin, which can overcome many of these obstacles. ⁽⁹⁾

Ivermectin: mechanism of action and benefits

Mechanism of action

Ivermectin is a broad-spectrum antiparasitic agent that has gained importance in the treatment of scabies. It acts by binding to glutamate-regulated chloride channels in the nervous system of mites. This binding increases the flow of chloride ions across cell membranes, leading to paralysis and ultimately death of the parasite. Unlike permethrin, which remains on the skin surface, ivermectin is taken orally and distributed in the body, making it effective against mites nestled deeper in the epidermis. This systemic action is particularly important in severe cases such as scabies, where mite numbers are extremely high. (^{(1)  (1)  ())}

Ease of administration

One of the most noticeable advantages of ivermectin is the simplicity of dosing. Treatment typically consists of a single oral dose of 200 µg/kg, followed by a second dose after 7-14 days to eliminate mites that have hatched from surviving eggs. This ease of application eliminates many of the problems associated with adherence to therapeutic recommendations associated with topical therapies. Elderly patients, people with physical limitations and those in care facilities or crowded environments benefit greatly from oral administration as it avoids the difficulties associated with applying the cream to the entire body. (^{(1)  (2)  ())}

Effectiveness in clinical practice

Numerous clinical studies have shown that ivermectin achieves comparable or even better cure rates compared to permethrin. Its role in mass drug administration (MDA) programmes has been particularly significant. The community-wide use of ivermectin has been shown to break transmission cycles, reduce re-infection and control outbreaks in care homes, schools and refugee camps. In addition, oral treatment allows for easy treatment of asymptomatic carriers, who are often silent sources of re-infection but may resist local therapy due to inconvenience or social stigma. (¹²⁾

Safety profile

Ivermectin has a well-established reputation for safety due to decades of use worldwide in the control of parasitic diseases such as onchocerciasis and lymphatic filariasis. Most side effects are mild and transient, involving headaches, dizziness or gastrointestinal complaints. Serious side effects are rare at standard doses. However, caution is advised for specific groups: children weighing less than 15 kilograms, pregnant women and breastfeeding mothers, for whom safety data are still limited. (¹²⁾

Overcoming resistance problems

Ivermectin also solves one of the most pressing problems in the treatment of scabies: suspected resistance to permethrin. Because ivermectin acts through a completely different molecular target, cross-resistance between the two drugs is unlikely. This makes it particularly valuable in regions or communities where permethrin treatment failures are common. In severe or refractory cases, the combination of oral ivermectin with topical permethrin has shown even greater efficacy, highlighting their potential synergy. (¹³⁾

A better alternative

In summary, ivermectin offers several advantages that directly overcome the disadvantages of permethrin. Oral administration provides better compliance, systemic distribution provides wider coverage and efficacy in cases of resistance reinforces its role in long-term scabies control. With the growing body of evidence and global experience, ivermectin is increasingly recognised not only as a backup option, but as a first-line therapy both for individual patients and as part of large-scale public health interventions.

Why ivermectin is superior to permethrin in the treatment of scabies

Different mechanisms and modes of administration

5% permethrin cream works by binding to sodium channels in the nerve cells of mites, leading to paralysis and death. Although it is very effective under controlled conditions, its topical application makes successful treatment dependent on correct application. Studies show that inadequate coverage of body areas, premature washing off or missed doses are among the most common causes of treatment failure. In contrast, ivermectin is an oral drug that distributes systemically. It acts on glutamate-regulated chloride channels in the nervous system of mites, causing hyperpolarisation and death. Because the drug acts from within the host body, it ensures exposure of mites in hard-to-reach areas (under fingernails, scalp or in eczema scabs) where topical therapy often fails. This systemic activity is particularly valuable in patients with extensive skin lesions or limited ability to apply creams alone. (¹⁴⁾

Comparative effectiveness: data from clinical trials

Randomised controlled trials have consistently compared the two drugs. A landmark multicentre study published in the New England Journal of Medicine (1995) showed that a single dose of oral ivermectin achieved cure rates comparable to permethrin after two applications, especially when combined with a second dose of ivermectin given 7-14 days later. (¹⁵⁾  More recent reviews, including a 2018 Cochrane systematic review of scabies treatment, have found that permethrin remains slightly more effective for scabies without complications when adherence is ideal. However, in clinical practice, oral administration of ivermectin yields better long-term results, as patient adherence is significantly higher^. (¹⁶⁾

Advantages in the case of epidemics and community control

Outbreaks of disease in care facilities highlight the logistical advantage of ivermectin. In indigenous communities in Australia, mass administration of ivermectin (at doses of 200 μg/kg, repeated weekly) reduced the incidence of scabies from over 50% to under 5% within a few months, a result difficult to achieve with topical creams. Similarly, in French nursing homes, control of outbreaks with ivermectin produced faster results than permethrin, mainly due to the ease of treating all residents simultaneously. (¹⁷⁾

Compliance with recommendations and patient experience

Patient compliance plays a key role in determining actual success. Permethrin requires thorough application to the entire body, leaving it on for 8-14 hours and often reapplying after a week. For infants, elderly or disabled patients, this process can be exhausting and error-prone.

In contrast, ivermectin requires only one oral dose, repeated after 7-14 days. Studies show that adherence rates for ivermectin exceed 90%, compared to much lower rates for permethrin , where patients often skip the topical therapy steps. This practical ease of use contributes to the higher overall efficacy of ivermectin outside the closely monitored clinical trials. ⁽¹⁸⁾

Safety, tolerance and limitations

Both drugs are generally safe. Permethrin occasionally causes skin irritation, itching or burning, which can be mistaken for the severity of an infection. Ivermectin is well tolerated and the most common side effects are mild gastrointestinal upset, dizziness or fatigue. Serious adverse events are rare. However, the use of ivermectin is limited in children weighing less than 15 kg and is not recommended during pregnancy due to limited safety data. In these groups, permethrin remains the drug of first choice. For adults, including immunocompromised patients and patients with scabies, ivermectin is often a better choice. (¹⁸⁾

Ivermectin for high-risk patients and the impact on public health

Scabies and immunocompromised patients

Scabies, also known as Norwegian scabies, is the most severe form of infestation, characterised by excessive keratinisation of the skin and the presence of millions of mites. It is often seen in immunocompromised individuals, including those with HIV/AIDS, transplant recipients or patients on long-term corticosteroid therapy. Topical application of permethrin, although theoretically effective, often fails in these cases due to high mite densities and difficulty in penetrating thick scabs. (^{19)  (20)}

In such situations, oral ivermectin has a clear advantage. Because it acts systemically, it bypasses the limitations associated with topical absorption and directly controls mites throughout the body. Clinical guidelines from Australia and France recommend multiple doses of ivermectin in combination with keratolytics, and sometimes topical agents, as the preferred treatment strategy for scabies. This regimen not only improves patient outcomes, but also reduces the high risk of transmission by these individuals, who often act as 'super-spreaders' in community outbreaks. (^{19)  (20)}

Scabies as a neglected tropical disease

In addition to individual cases, scabies is increasingly recognised as a global health burden. In 2017. The World Health Organisation officially added scabies to the list of neglected tropical diseases (NTDs). The disease disproportionately affects resource-limited settings, particularly in sub-Saharan Africa, South Asia and remote indigenous communities, where prevalence among children can exceed 30%. Complications of scabies - secondary bacterial infections, sequelae after streptococcal infection such as rheumatic heart disease and kidney damage - increase its impact on public health. (²¹⁾

Mass drug administration and additional benefits

Mass drug administration (MDA) experiences in Africa and the Pacific highlight the public health potential of ivermectin. In Ghana, Tanzania and the Solomon Islands, community-wide distribution of ivermectin to control filariasis led to an incidental and dramatic reduction in the incidence of scabies. In Fiji, a randomised clinical trial showed that MDA with ivermectin reduced the incidence of scabies by more than 90% in treated villages over one year. These results demonstrate the scalability of ivermectin both as a targeted therapy and as a community-level control tool. (²²⁾

Conclusions

1. In summary, the evidence suggests that ivermectin is not only essential for severe cases such as scabies, but also forms the basis of global scabies elimination strategies. By leveraging existing drug delivery platforms for other tropical diseases, ivermectin offers a cost-effective and practical way to reduce the global burden of this neglected disease.

Disclaimer

This article has been written for educational purposes and is intended to raise awareness of the substance under discussion. It is important to note that the article is about the substance in general - it is not a description of a specific product (chemical reagent). We do not suggest using chemical reagents on humans - this is prohibited by law. For a product to be used for treatment, it must be registered as a medicine. The information contained in the text is based on available scientific research and is not intended as medical advice or to promote self-medication. The reader should consult a qualified health professional for all health and treatment decisions.

References

1. Talaga-Ćwiertnia, K. (2021). Sarcoptes infestation. What is already known and what is new about scabies at the beginning of the third decade of the 21st century? Pathogens, 10(7), 868.
2. Delaš Aždajić, M., Bešlić, I., Gašić, A., Ferara, N., Pedić, L. and Lugović-Mihić, L. (2022). Increased prevalence of scabies at the beginning of the 21st century: what do reports from Europe and the world show? Life, 12(10), 1598.
3. Jannic, A., Bernigaud, C., Brenaut, E. and Khosidov, O. (2018). Scabies-induced itching. Dermatology clinics, 36(3), 301-308.

Banerji, A. (2015). Scabies. Paediatrics and child health, 20(7), 395-398.

1. Hussain, A. H., Hussain, N. M. and Ali, S. (2021). A review of epidemiology, transmission, pathogenesis and treatment of scabies. The British Student Doctor Journal, 5(1), 54-61.
2. El-Moamly, A. A. (2021). Scabies as part of the World Health Organization's Neglected Tropical Diseases Action Plan 2021-2030: what we know and what we need to do to ensure global control. Tropical medicine and health, 49(1), 64.
3. Ranjkesh, M. R., Naghili, B., Goldust, M. and Rezaee, E. (2013). Efficacy of permethrin 5% versus oral ivermectin in the treatment of scabies. Annals of parasitology, 59(4).
4. Yürekli, A. (2022). Is there really resistance to permethrin treatment of scabies? In vitro killing effect of permethrin on Sarcoptes scabiei in patients with resistant scabies. Dermatologic Therapy, 35(3), e15260.
5. Mbuagbaw, L., Sadeghirad, B., Morgan, R. L., Mertz, D., Motaghi, S., Ghadimi, M., ... & Reichert, F. (2024). Treatment failure in scabies: a systematic review and meta-analysis. British Journal of Dermatology, 190(2), 163-173.
6. Martin, R. J., Robertson, A. P., & Choudhary, S. (2021). Ivermectin: anthelmintic, insecticide and more. Trends in parasitology, 37(1), 48-64.
7. Martin, R. J., Robertson, A. P. and Choudhary, S. (2021). Ivermectin: anthelmintic, insecticide and more. Trends in parasitology, 37(1), 48-64.
8. Chhaiya, S. B., Mehta, D. S. and Kataria, B. C. (2012). Ivermectin: pharmacology and therapeutic applications. Int J Basic Clin Pharmacol, 1(3), 132-139.
9. Simonart, T. and Lam Hoai, X. L. (2024). The growing threat of drug-resistant human scabies: current knowledge and future directions. Journal of clinical medicine, 13(18), 5511.
10. Lobo, Y. and Wheller, L. (2021). A narrative review of the role of topical permethrin and oral ivermectin in the treatment of childhood scabies. Australasian Journal of Dermatology, 62(3), 267-277.
11. Meinking, T. L., Taplin, D., Herminda, J. L., Pardo, R. and Kerdel, F. A. (1995). Treatment of scabies with ivermectin. New England Journal of Medicine, 333(1), 26-30.
12. Rosumeck, S., Nast, A., Dressler, C. and Cochrane Infectious Diseases Group. (1996). Ivermectin and permethrin in the treatment of scabies. Cochrane Database of Systematic Reviews, 2018(4).
13. Middleton, J., Walker, S. L., House, T., Head, M. G. and Cassel, J. A. (2019). Ivermectin in the control of scabies outbreaks in the UK. The Lancet, 394(10214), 2068-2069.
14. Genuino, R. F., Batac, M. C. F. R., Capule, F. R., Ednalino, K. A. G., Garcia Jr, F. B., Ladia, M. A. J., ... and Cagayan, M. S. F. S. (2022). Comparative efficacy and safety of oral ivermectin, topical permethrin and their combination in the treatment of scabies: a systematic literature review. Journal of the Philippine Dermatological Society, 31(1), 7-19.
15. Hall, M., Forsyth, A., Du, W., Carletti, M., & Weis, S. (2025). Public health challenges: diagnosis and treatment of scabies.
16. Salvador, F., Lucas-Dato, A., Roure, S., Arsuaga, M., Pérez-Jacoiste, A., García-Rodríguez, M., ... and Molina, I. (2021). Efficacy and safety of a single dose of ivermectin in the treatment of uncomplicated strongyloidosis in immunocompromised patients (ImmunoStrong study): study protocol. Pathogens, 10(7), 812.
17. Cox, V., Fuller, L. C., Engelman, D., Steer, A., & Hay, R. J. (2021). Estimating the global burden of scabies: what more do we need? British Journal of Dermatology, 184(2), 237-242.

Mutono, N., Basáñez, M. G., James, A., Stolk, W. A., Makori, A., Kimani, T. N., ... & Thumbi, S. M. (2024). Elimination of onchocerciasis (river blindness) transmission by long-term mass administration of ivermectin with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis. The Lancet Global Health, 12(5), e771-e782.